Sergej Konoplev

Harrison Medical Center — United States

Medicine · Health Sciences

46h-index9.4kcitations245works9.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(95), Lymphoma Diagnosis and Treatment(53), Chronic Lymphocytic Leukemia Research(46), Chronic Myeloid Leukemia Treatments(36), Acute Lymphoblastic Leukemia research(31)

Publications245 total

Corrigendum to “Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group” [Modern Pathology. 2024;37(2):100406]
Modern Pathology·2026Open Access
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Nature Cancer·2024· 28 cited
Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation
American Journal of Clinical Pathology·2024Open Access
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group
Modern Pathology·2023· 4 citedOpen Access
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro
Biochemical Pharmacology·2023· 18 citedOpen Access
Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism
Blood·2023· 2 cited
Abstract A24: Targeting mitochondrial metabolism following Induction Chemotherapy eradicates Acute Myeloid Leukemia at the level of Minimal Residual Disease
Blood Cancer Discovery·2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and purine biosynthesis
2023· 2 citedOpen Access
Data from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Data from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Supplementary Figure Legend from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
2023Open Access
Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
2023Open Access
Supplementary Figure 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Data from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
2023Open Access
Supplementary Table 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Supplementary Figure 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
2023Open Access
Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
2023Open Access
Data from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Marina Konopleva(24), L. Jeffrey Medeiros(22), Michael Andreeff(19), Hagop M. Kantarjian(18), Carlos E. Bueso‐Ramos(11), Elias Jabbour(10), Jeffrey L. Jorgensen(10), Jörge E. Cortes(8), Nitin Jain(7), Sa A. Wang(7), Guillermo Garcia‐Manero(7), Farhad Ravandi(7), C. Cameron Yin(7), Joseph D. Khoury(7), Steven M. Kornblau(6), Sherry Pierce(6), R. Eric Davis(6), Shaoying Li(6), Weina Chen(6), Pei Lin(6)